Wikimore

Opiranserin
Clinical data
Other names	VVZ-149; VVZ-000149
Routes of; administration	Intravenous
Identifiers
	IUPAC name 4-Butoxy-N-([4-(dimethylamino)oxan-4-yl]methyl)-3,5-dimethoxybenzamide;
CAS Number	1441000-45-8;
PubChem CID	71566778;
UNII	AP031EC2NI;
Chemical and physical data
Formula	C21H34N2O5
Molar mass	394.512 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NCC1(N(C)C)CCOCC1)C2=CC(OC)=C(OCCCC)C(OC)=C2;
	InChI InChI=1S/C21H34N2O5/c1-6-7-10-28-19-17(25-4)13-16(14-18(19)26-5)20(24)22-15-21(23(2)3)8-11-27-12-9-21/h13-14H,6-12,15H2,1-5H3,(H,22,24); Key:JQUVQWMHZSYCRQ-UHFFFAOYSA-N;

Opiranserin (INNTooltip International Nonproprietary Name; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC₅₀Tooltip Half-maximal inhibitory concentration = 0.86 μM), purine P2X₃ receptor antagonist (IC₅₀ = 0.87 μM), and serotonin 5-HT_2A receptor antagonist (IC₅₀Tooltip Half-maximal inhibitory concentration = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain.^[1]^[2]^[3]^[4] As of April 2017, it is in phase II clinical trials for this indication.^[3] The INNTooltip International Nonproprietary Name of the drug was issued in 2017.^[2] Approved for post-operative pain management in South Korea in December of 2024.

References

Clinical data

Other names	VVZ-149; VVZ-000149
Routes of administration	Intravenous
Identifiers
IUPAC name 4-Butoxy-N-([4-(dimethylamino)oxan-4-yl]methyl)-3,5-dimethoxybenzamide
CAS Number	1441000-45-8
PubChem CID	71566778
UNII	AP031EC2NI
Chemical and physical data
Formula	C₂₁H₃₄N₂O₅
Molar mass	394.512 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(NCC1(N(C)C)CCOCC1)C2=CC(OC)=C(OCCCC)C(OC)=C2
InChI InChI=1S/C21H34N2O5/c1-6-7-10-28-19-17(25-4)13-16(14-18(19)26-5)20(24)22-15-21(23(2)3)8-11-27-12-9-21/h13-14H,6-12,15H2,1-5H3,(H,22,24) Key:JQUVQWMHZSYCRQ-UHFFFAOYSA-N